Doxy-chem caps. 500mg 30 pieces

$6.32

Doxy-chem caps. 500mg 30 pieces

Quantity:

SKU: 01252300618 Categories: , Tags: ,

Description

Composition
Active substance:
1 tablet dobesilate calcium (in the form of calcium dobesilate monohydrate 521.51 mg) – 500.00 mg.
Excipients:
Cornstarch – 25.164 mg magnesium stearate – 8,326 mg; shell capsule body: Titanium dioxide E171 – 0.8640 mg Iron oxide yellow dye E172-0,1440 mg; cap: black iron oxide coloring E 172 – 0.1920 mg indigo carmine dye E132 – 0.1728 mg Titanium dioxide E171 – 0.4800 mg ferric oxide yellow colorant E172 – 0.5760 mg to 96 mg of gelatin.
Description:
Hard gelatin capsule № 0 capsule body opaque light yellow, opaque cap dark green color.
The contents of the capsule: Powder from white to yellowish-white in color.
Presence of conglomerates, which are converted to free-flowing powder is lightly pressed glass rod.
Product form:
Capsules 500 mg. 10 capsules in blister PVC / AL. 3 blisters with instructions for use in a cardboard pack.
Contraindications
Increased sensitivity to calcium dobesilate or any component of the formulation, gastric ulcer and duodenum 12 (in the acute stage), bleeding from the gastrointestinal tract, kidney and liver disease, hemorrhage caused by anticoagulation; pregnancy (I trimester), children’s age (13 years).
Dosage
500 mg
Indications
Vascular lesions with increased fragility and permeability of capillary (diabetic retinopathy and nephropathy) and other microangiopathy associated with various cardiovascular and metabolic diseases.
Venous insufficiency of varying severity and its consequences (predvarikoznoe state with phenomena of tissue swelling, pain, paresthesias, stagnant dermatosis; superficial phlebitis, varicose veins, trophic ulcers).
Interaction with other drugs
Cases of calcium dobesilate drug interactions has not yet been identified.
Overdose
Cases of overdose were reported.
pharmachologic effect
Pharmacological group:
Angioprotective means.
Pharmacodynamics:
Angioprotector reduces vascular hyperpermeability and increases capillary resistance walls, improves and drainage function of lymphatic vessels, moderately reduces platelet aggregation and blood viscosity, increases the elasticity of the erythrocyte membrane. The action is due to some extent to the increase of plasma kinins.
Pharmacokinetics:
Rapidly absorbed in the gastrointestinal tract. The maximum plasma concentration is reached at 6 hours after ingestion. Binding to plasma proteins is 20-25%. Practically it does not penetrate the blood-brain barrier.
Excreted by the kidneys (approximately 50%) and in the intestine (about 50%), mainly in unmodified form for 24 hours, 10% – in the form of metabolites. The half – 5 hours.
In very small amounts (0.4 ug / ml after the drug Hour 1.5 g) excreted in breast milk.
Pregnancy and breast-feeding
There are no adequate and well-controlled studies of the safety in pregnant and lactating women is not carried out. Use of the drug is contraindicated in the first trimester of pregnancy. In the second and third trimesters of pregnancy, the drug is prescribed only for health reasons, if the expected effect of the application exceeds the potential risk to the fetus.
In the appointment during lactation is necessary to solve the issue of termination of breastfeeding.
Conditions of supply of pharmacies
On prescription.
side effects
Classification of adverse reactions of frequency: often – 1-10%, rarely – 0.1-1%, rarely – 0.01-0.1%, very rare, including isolated cases –
Disorders of the gastrointestinal tract. Rare: nausea, diarrhea, vomiting.
Violations of the skin and subcutaneous tissue. Rare: allergic reactions (itching, rash).
Common disorders. Rare: fever, chills.
Violations by musculoskeletal and connective tissue. Rare: arthralgia.
Blood disorders and lymphatic system. In some cases: agranulocytosis. The reaction is reversible and disappears after discontinuation of therapy.
special instructions
The drug can be administered prophylactically.
When agranulocytosis symptoms (fever, headache, chills, weakness, pain on swallowing, inflammation of the oral mucosa) should seek immediate medical attention and to hold blood count.
Calcium dobesilate can affect the results of laboratory tests to determine the level of creatinine.
Effects on ability to drive and use machines
The drug has no adverse effect on the ability to drive vehicles and operate machinery.
Storage conditions
At temperatures above 25 ° C in a consumer package.
Keep out of the reach of children.
Dosing and Administration
The inside is not liquid, during a meal time. Assign to 500 mg three times a day for 2-3 weeks, then to reduce the dose of 500 mg 1 time per day. In the treatment of retinopathy and microangiopathy administered 500 mg 3 times a day for 4-6 months, then the daily dose reduced to 500 mg 1 time per day. The course of treatment – from 3-4 weeks to several months, depending on the therapeutic effect.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

STADA

There are no reviews yet.

Add your review